T HE BENEFITS of tacrolimus in solid organ transplantation are well recognized. I-I> The aim of the present study is to examine the outcome of primary liver transplantation (LTx) under tacrolimus for various age groups over a long-term in 1000 consecutive patients from a single center.
MATERIAL
The first 1000 primary L Tx recipients under tacrolimus from August 1989 to December 1992 were followed until August 1997 (mean follow-up 77, range 56 to 96, months). The characteristics of the patients and immunosuppressive protocol have been described before in this population. 7 There were 75 infants (s2 years), 91 children (>2 s18 years), 630 adults (> 18 s60 years), and 204 seniors «60 years). Of the recipients, 84.1% were hospital bound at the time of LTx, and 141 donors were above age 50 years.
RESULTS
Patient and graft survival for various age groups is shown in Table 1 . The difference in patients survival and graft survival for various age groups were highly significant, p = .0006 and .0000, respectively (log rank). The level of immunosuppression, liver function (mean total bilirubin, AST, ALT, alkaline phosphatase, GGTP), and the renal function at various time points is shown in Table 2 .
Adverse Events
The overall prevalence of hypertension requiring antihypertensive medication, insulin dependent diabetes mellitus, hyperkalemia (k+ > 5.0 mEq/L), and mean cholesterol values are shown in Table 2 . Three infants and children (2%) and 23 adults and seniors (2.8%) underwent kidney transplant for end-stage renal disease. In addition, 12 adults and seniors are currently on hemodialysis. Posttransplant Iymphoproliferative disorder (PTLD) was observed in 19 infants and children (11.4%) and 16 adults and seniors (1.9%). Seventy-nine percent of infants and children and 69% of adults and seniors are currently alive following the diagnosis of PTLD. DeNovo non lymphoid malignancy was observed in 57 adults and seniors (6.8%) but not in infants or children. These consisted of 20 squamous or basal cell skin cancers, 2 melanoma of the skin, 8 lung cancers, 7 oropharyngeal cancers, 5 gastrointestinal cancers, 5 genitourinary cancers, 3 breast cancers, 2 Kaposi's sarcoma, and 5 other miscellaneous cancers. Fifty-eight percent of these patients are still alive. Graft loss and death related to chronic rejection accounted for 13 adults and seniors (1.6%). Most of them had associated risk factors such as life-threatening sepsis requiring withholding of immunosuppression, cytomegalo or hepatitis C or hepatitis B viral infection, noncompliance of the patients taking immunosuppression.
DISCUSSION
The initial benefit of tacrolimus reported in our early experience has been maintained in the long term. While patient and graft survival in adults and seniors continue to drop at a rate of 3 to 4% every year beyond 2 years, survival for infant and children remains stable. Graft loss due to acute or chronic rejection is rare under tacrolimus-based immunoprophylaxis. The common causes of graft loss in the long term include recurrence of the disease, cardiorespiratory failure, cerebrovascular accidents, noncompliance of the patients. and denovo cancers. Relatively stable liver and renal function has been observed in the long term. About 70% of the patients remain without steroids beyond 1 year. Nephrotoxicity leading to end-stage renal failure is less than five percent. Incidence of PTLD and denovo cancers are comparable with conventional immunosuppression. 8 • 9 Lesser incidence of acute or chronic rejection; lesser inci- 
